This is a non-core endpoint: only basic statistics are computed.
Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites
CD2_BENIGN_LIPO_SKIN_NOS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D17
- Name in latin
- Neoplasma benignum lipomatosum cutis sive textus subcutanei locis aliis sive non specificatis
Similar endpoints
↥List of similar endpoints to
Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites
based on the number of shared cases.
Similar with more cases:
- Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites
- Benign lipomatous neoplasm
- Benign lipomatous neoplasm
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 260 | 161 | 99 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.04 |
| Median age at first event (years) | 52.82 | 50.98 | 55.81 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 230
- Matched controls
- 2299
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D17.3
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites
+∞
323.0
229
*
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
18.9
44.1
70
52
D17.1
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk
14.0
20.4
35
29
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
16.9
16
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
171.2
15.7
16
*
D17.9
ICD-10 Finland
Benign lipomatous neoplasm, unspecified
19.5
15.5
23
13
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
14.7
14
*
D17.2
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of limbs
11.1
13.9
26
26
130
Kela drug reimbursment
Malignant tumour
+∞
13.7
13
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
12.6
12
*
QDE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in lower limb
11.0
12.3
23
23
QBE99
NOMESCO Finland
Other excision or repair of lesion of skin of trunk
12.8
11.6
20
17
QXE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in uspecified region
37.1
11.4
14
*
H02AB02
ATC
dexamethasone; systemic
26.6
11.3
15
6
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
7.6
11.2
26
38
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
115.0
10.5
11
*
TQW99
NOMESCO Finland
Other minor procedure on skin
8.6
10.4
22
28
QCE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in upper limb
9.8
9.7
19
21
PJA12
NOMESCO Finland
Sentinel node biopsy
104.1
9.5
10
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
9.4
9
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
9.4
9
*
R4110
NOMESCO Finland
Physiotherapy
2.7
8.6
70
323
115
Kela drug reimbursment
Breast cancer
+∞
8.4
8
*
116
Kela drug reimbursment
Prostate cancer
+∞
8.4
8
*
D17.0
ICD-10 Finland
Benign lipomatous neoplasm of skin and subcutaneous tissue of head, face and neck
10.6
7.6
14
14
K03.65
ICD-10 Finland
Deposits [accretions] on teeth betel
2.8
7.6
55
234
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.3
7
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
+∞
7.3
7
*
ZXA05
NOMESCO Finland
Left side
2.4
7.2
69
344
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.7
7.1
52
224
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.3
7.0
74
389
Z51.5
ICD-10 Finland
Palliative care
8.7
6.9
14
17
Z71.2
ICD-10 Finland
Person consulting for explanation of investigation findings
2.4
6.8
65
324
WX408
NOMESCO Finland
General anesthesy, balanced
2.4
6.7
66
336
R4190
NOMESCO Finland
Nutritional therapy
11.5
6.4
11
10
JN4BD
NOMESCO Finland
Extensive body CT
4.8
6.3
20
45
L01BC06
ATC
capecitabine; oral
+∞
6.3
6
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
251
2235
4.55
7.18
15.0
13.2
3.9
4.0
mmol/l
1.59
244
2163
154
1103
1.97
6.56
9.5
6.3
3.9
4.2
e9/l
1.51
132
950
122
823
1.91
6.07
4.3
3.5
36.4
36.1
g/l
0.26
113
762
236
2039
2.71
5.43
14.0
9.9
81.2
80.6
ml/min/173m2
0.16
205
1634
13
30
4.51
5.36
1.2
1.2
—
—
—
0
0
13
30
4.51
5.36
1.2
1.2
—
—
—
0
0
250
2232
4.12
5.34
14.7
13.2
139.7
139.8
mmol/l
0.24
243
2161
242
2127
2.99
5.18
14.2
11.0
25.0
21.5
mg/l
0.73
185
1585
193
1556
1.93
5.11
7.8
5.0
78.2
73.9
u/l
0.45
178
1431
234
2037
2.49
4.87
4.9
4.7
1.8
2.5
mu/l
0.58
220
1862
165
1310
1.71
4.12
4.3
4.0
—
2581.1
—
0
15
93
646
1.68
3.77
4.2
2.0
2.4
2.3
mmol/l
2.15
83
546
225
1980
2.01
3.70
17.0
12.4
40.7
40.5
%
0.17
181
1428
125
941
1.63
3.69
6.0
5.3
1.2
1.2
mmol/l
0.11
109
818
114
842
1.63
3.61
3.1
3.4
—
—
—
0
0
59
370
1.77
3.42
3.7
2.0
2.5
2.4
mmol/l
2.50
51
315
77
522
1.67
3.37
3.1
2.7
0.3
0.4
e6/l
0.42
55
380
40
224
1.93
3.30
3.6
2.5
9.1
6.5
umol/l
0.33
35
195
250
2320
3.02
3.20
10.9
8.4
24.9
25.8
u/l
0.32
241
2226
111
834
1.58
3.17
2.5
2.3
78.6
77.8
nmol/l
0.11
100
739
62
408
1.68
3.01
2.2
1.8
—
—
—
0
0
92
670
1.58
2.97
3.0
2.8
—
—
—
0
0
113
869
1.53
2.83
2.2
1.9
98.0
96.2
pmol/l
0.14
64
424
44
267
1.78
2.83
22.2
21.6
1.7
1.3
inr
—
5
35
9
23
4.01
2.80
1.2
1.1
—
—
—
0
0
17
72
2.46
2.79
1.2
1.1
—
—
—
0
0
66
450
1.63
2.78
1.4
1.7
1.4
1.0
mg/l
0.74
39
357
112
871
1.50
2.61
5.4
4.8
1.2
1.2
mmol/l
0.22
100
774
51
336
1.64
2.45
3.3
2.5
0.6
0.7
ug/l
1.02
36
212
227
2069
1.77
2.44
5.6
6.0
39.1
40.1
mmol/mol
1.05
216
1929
168
1432
1.49
2.41
2.7
2.8
43.6
45.2
u/l
0.08
159
1330
16
71
2.34
2.39
1.3
1.1
—
—
—
0
0
140
1160
1.45
2.27
4.2
4.1
6.7
6.8
mmol/l
0.06
126
1069
27
152
1.87
2.22
3.3
3.6
81.3
80.3
ng/l
0.02
22
137
44
287
1.64
2.19
3.3
2.7
3.1
2.8
e6/l
0.07
23
136
48
322
1.60
2.14
3.1
2.5
0.6
1.2
e6/l
1.24
26
170
192
1705
1.48
2.06
3.8
3.9
14.6
14.8
pmol/l
0.39
182
1553
237
2214
1.80
1.96
4.1
4.6
4.7
4.7
mmol/l
0.19
223
2055
11
47
2.40
1.80
1.3
1.4
—
—
—
0
0
42
285
1.56
1.79
1.2
1.6
—
—
—
0
0
54
390
1.49
1.74
1.6
1.7
881.5
1173.8
nmol/l
1.77
36
296
20
112
1.85
1.70
2.0
1.5
—
—
—
0
0
239
2253
1.75
1.69
5.0
5.1
2.8
2.8
mmol/l
0.19
225
2084
6
19
3.21
1.67
1.3
1.1
—
—
—
0
0
65
492
1.43
1.64
4.2
3.3
22.0
25.0
%
0.76
32
208
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
44
2.32
1.55
2.3
2.3
0.3
0.3
u/ml
—
5
26
9
37
2.48
1.49
1.6
2.0
—
—
—
0
0
62
475
1.40
1.46
2.2
2.0
2.6
3.0
mg/l
0.59
46
404
31
208
1.56
1.41
1.3
1.6
—
—
—
0
0
21
128
1.70
1.38
1.4
1.3
—
—
—
0
0
5
17
2.98
1.36
1.0
1.0
—
—
—
0
0
30
204
1.53
1.29
1.3
1.6
—
—
—
0
0
18
285
0.60
1.25
6.1
6.6
—
—
—
0
0
77
628
1.32
1.21
5.3
3.6
1.6
1.8
ug/l
0.78
70
559
30
208
1.50
1.19
3.5
6.6
0.1
1.8
mmol/l
2.16
24
161
5
21
2.41
1.09
1.0
1.1
—
—
—
0
0
31
221
1.46
1.09
4.7
5.4
105.5
104.0
mmol/l
0.86
31
215
228
2168
1.42
1.06
4.6
4.6
6.0
6.0
mmol/l
0.08
211
1981
46
355
1.36
1.04
1.6
1.5
—
—
—
0
0
9
46
1.99
1.04
1.4
1.2
—
—
—
0
0
9
46
1.99
1.04
1.6
1.3
—
—
—
0
0
115
1005
1.26
1.04
3.0
3.4
0.0
0.0
estimate
0.00
21
172
11
61
1.84
1.00
1.1
1.5
—
—
—
0
0
32
234
1.42
0.99
2.1
2.4
26.9
24.1
%
0.38
26
206
25
174
1.48
0.99
1.5
4.0
127.4
238.0
ng/l
1.53
19
160
16
101
1.62
0.96
1.2
1.5
—
—
—
0
0
230
2200
1.39
0.93
4.2
4.5
1.5
1.5
mmol/l
0.15
216
2033
38
292
1.35
0.90
2.2
2.2
15.5
14.1
umol/l
0.58
33
269
174
1611
1.24
0.88
3.6
4.0
10.3
11.0
mm/h
0.30
160
1474
105
924
1.23
0.86
2.8
2.7
96.0
118.4
ug/l
0.91
96
857
8
45
1.80
0.85
1.3
1.1
—
—
—
0
0
114
1015
1.22
0.83
4.5
4.5
0.0
0.0
estimate
0.50
19
171
15
98
1.56
0.80
1.7
1.9
—
—
—
0
0
51
420
1.27
0.75
2.7
3.9
1222.7
197.2
ng/l
0.41
41
320
12
76
1.61
0.73
1.4
1.7
1.7
1.5
g/l
0.54
12
66
63
534
1.24
0.73
2.7
2.3
354.5
4416.4
umol/l
1.51
52
464
146
1346
1.19
0.70
3.1
3.0
—
—
—
0
0
5
27
1.87
0.69
1.6
1.3
173.8
303.7
pmol/l
—
5
19
114
1030
1.19
0.68
3.0
3.4
0.0
0.0
estimate
0.00
21
165
18
128
1.44
0.67
1.2
1.2
99.3
374.0
u/ml
0.81
18
115
5
28
1.80
0.66
1.4
1.5
—
—
—
0
0
42
344
1.26
0.65
1.5
1.4
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
7
112
0.61
0.59
1.3
1.3
—
—
—
0
0
24
186
1.32
0.57
1.4
1.9
—
—
—
0
0
220
2127
1.22
0.53
3.7
4.1
1.3
1.3
mmol/l
0.47
204
1942
48
555
0.83
0.50
3.0
3.5
0.0
0.0
estimate
0.50
20
167
10
69
1.47
0.45
1.1
1.4
—
—
—
0
0
7
51
1.38
0.44
1.3
1.1
—
—
—
0
0
73
805
0.87
0.43
3.3
3.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.4
—
1.2
—
0
10
8
59
1.37
0.41
1.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
94.4
—
0
5
7
105
0.66
0.40
1.7
2.1
1.2
1.2
%
—
7
105
0
18
0.00
0.40
0.0
1.0
—
564.5
—
0
13
0
18
0.00
0.40
0.0
1.0
—
41.9
—
0
12
15
115
1.32
0.40
1.1
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
21
170
1.26
0.38
2.6
3.0
—
—
—
0
0
6
42
1.44
0.36
1.3
1.2
—
—
—
0
0
6
42
1.44
0.36
1.2
1.3
—
—
—
0
0
67
614
1.12
0.32
2.6
2.8
1408.4
1124.2
ng/l
0.20
54
512
20
166
1.22
0.31
1.3
1.8
—
—
—
0
0
24
204
1.19
0.30
2.3
1.8
—
—
—
0
0
70
647
1.11
0.29
1.7
2.1
52.8
56.1
u/l
0.43
64
593
23
267
0.85
0.27
5.2
4.8
31.1
31.9
%
0.17
16
176
11
86
1.29
0.26
6.0
1.2
—
—
—
0
0
11
86
1.29
0.26
6.0
1.2
3.2
3.9
g/l
—
6
62
10
78
1.29
0.24
3.2
2.5
0.2
0.1
e6/l
—
10
73
5
38
1.32
0.23
5.0
5.3
288.6
370.3
umol/l
—
5
33
54
500
1.10
0.22
1.6
1.5
17.2
21.4
nmol/l
1.94
49
421
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
52
1.16
0.19
2.5
3.3
—
—
—
0
0
20
177
1.14
0.17
4.3
7.2
125.5
123.3
g/l
0.24
20
172
8
73
1.10
0.16
3.4
1.7
—
—
—
0
0
10
83
1.21
0.15
1.6
1.8
—
—
—
0
0
85
815
1.06
0.15
2.8
3.4
16.9
34.4
ng/l
2.84
54
558
36
388
0.92
0.15
1.2
1.3
1.5
7.2
u/ml
2.41
17
146
38
404
0.93
0.12
1.3
1.3
10.7
32.0
iu/ml
—
6
136
6
56
1.07
0.08
1.0
1.3
0.5
218.4
e6/l
—
6
43
7
80
0.87
0.07
1.6
1.9
—
—
—
0
0
11
99
1.12
0.06
2.1
3.4
2.0
2.0
mmol/l
—
6
68
18
188
0.95
0.02
3.2
2.9
5.9
5.8
kpa
0.31
18
182
50
493
1.02
0.01
1.3
1.3
0.6
1.7
u/ml
1.51
11
141
12
123
0.97
0.00
5.3
2.9
4.5
4.5
pmol/l
0.07
12
106
19
187
1.02
0.00
1.3
2.4
2.4
8.0
ug/l
2.86
14
161
66
663
0.99
0.00
2.4
2.0
240.4
177.3
u/l
0.29
59
625
0
5
0.00
0.00
0.0
3.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
5
59
0.84
0.00
1.2
1.2
—
17.3
—
0
11
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
7
70
1.00
0.00
2.7
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
9.5
—
0
8
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.5
—
72.2
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_LIPO_SKIN_NOS_EXALLC – Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).